ad image

HUMIRA

1 / 1
Eli Lilly and Company
Positive Results

Lilly Presents Positive Results for Taltz® vs. Humira®in Patients with Active Psoriatic Arthritis

Eli Lilly and Company

PR-M06-19-NI-023Jun 18, 2019
AbbVie
Legal

AbbVie Resolves HUMIRA® (adalimumab) U.S. Patent Litigation with Boehringer Ingelheim

AbbVie

PR-M05-19-NI-056May 20, 2019
Entyvio Outperforms Humira As an Ulcerative Colitis Therapy
Drug Development

Entyvio Outperforms Humira As an Ulcerative Colitis Therapy

Nice Insight

PAO-M03-19-NI-020Mar 12, 2019
Pfizer to License AbbVie’s Humira IP
Licensing Agreement

Pfizer to License AbbVie’s Humira IP

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-M12-18-NI-006Dec 05, 2018
Humira Patent Disputes between Novartis and Abbvie Settled
Patent

Humira Patent Disputes between Novartis and Abbvie Settled

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-M10-18-NI-021Oct 22, 2018
GlobalData Predicts Strong Sales for Humira Biosimilars in Europe
Biosimilars

GlobalData Predicts Strong Sales for Humira Biosimilars in Europe

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-M05-18-NI-006May 10, 2018
Another Biosimilar Gets FDA Nod
Biosimilar

Another Biosimilar Gets FDA Nod

Guy Tiene

Nice Insight

PAO-M09-17-NI-011Sep 08, 2017
1 / 1